| Identification | Back Directory | [Name]
BCX-4161 | [CAS]
918407-35-9 | [Synonyms]
BCX-4161
Avoralstat
Avoralstat(BCX-4161)
BCX-4161; BCX 4161; BCX4161; AVORALSTAT
2-Pyridinecarboxylic acid, 3-[2-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]-4-ethenyl-5-methoxyphenyl]-6-[[(cyclopropylmethyl)amino]carbonyl]-
Serine proteases,Avoralstat,BCX 4161,hereditary,bradykinin,Threonine proteases,angioedema,Inhibitor,Serine endopeptidases,BCX-4161,inhibit,Ser/Thr Protease,oral | [EINECS(EC#)]
811-719-1 | [Molecular Formula]
C28H27N5O5 | [MDL Number]
MFCD28502152 | [MOL File]
918407-35-9.mol | [Molecular Weight]
513.54 |
| Chemical Properties | Back Directory | [density ]
1.38±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:50.0(Max Conc. mg/mL);97.36(Max Conc. mM) | [form ]
A solid | [pka]
2.99±0.36(Predicted) | [color ]
White to yellow |
| Hazard Information | Back Directory | [Uses]
Avoralstat (BCX4161), a potent and orally active plasma kallikrein (PKK) inhibitor, is used for hereditary angioedema research[1][2]. | [References]
[1] Aygoren-Pursun E, et al. Prophylaxis of hereditary angioedema attacks: A randomized trial of oral plasma kallikrein inhibition with avoralstat. J Allergy Clin Immunol. 2016 Sep;138(3):934-936.e5. DOI:10.1016/j.jaci.2016.03.043
[2] Cornpropst M, et al. Safety, pharmacokinetics, and pharmacodynamics of avoralstat, an oral plasma kallikrein inhibitor: phase 1 study. Allergy. 2016;71(12):1676-1683. DOI:10.1111/all.12930 |
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
| Company Name: |
InvivoChem
|
| Telephone: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|